This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murillo, O. Articles by Melero, I. Search for Related Content PubMed PubMed Citation Articles by Murillo, O. Articles by Melero, I. Related Collections Cancer Immunology Cancer Immunology: Immunotherapy

Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies

Centro de Investigación Médica aplicada and Clínica Universitaria, Universidad de Navarra, Pamplona, Spain

Immunotherapeutic monoclonal antibodies (mAbs) can be defined as those that exert their functions by tampering with immune system cell molecules, causing an enhancement of antitumor immune responses. Some of these antibodies are agonistic ligands for surface receptors involved in the activation of lymphocytes and/or antigen-presenting cells, whereas others are antagonists of mechanisms that normally limit the intensity of immune reactions. Several mAbs of this category have been described to display in vivo antitumor activity in mouse models. Only anti-CTLA-4 (CD152) mAb has entered clinical trials, but the preclinical effects described for anti-CD40, anti-CD137 (4-1BB), anti-CD102 (intercellular adhesion molecule-2), and regulatory T cell-depleting mAbs should lead to their prompt clinical development. Their use in combination with immunizations against tumor antigens has been reported to be endowed with synergistic properties. This new group of antitumor agents holds promise for at least additive effects with conventional therapies of cancer and deserves intensive translational research.

This article has been cited by other articles:

				E. Esplugues, J. Vega-Ramos, D. Cartoixa, B. N. Vazquez, I. Salaet, P. Engel, and P. Lauzurica Induction of tumor NK-cell immunity by anti-CD69 antibody therapy Blood, June 1, 2005; 105(11): 4399 - 4406. [Abstract] [Full Text] [PDF]

				G. Mazzolini, C. Alfaro, B. Sangro, E. Feijoo, J. Ruiz, A. Benito, I. Tirapu, A. Arina, J. Sola, M. Herraiz, et al. Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas J. Clin. Oncol., February 10, 2005; 23(5): 999 - 1010. [Abstract] [Full Text] [PDF]

				M. Z. Lin, M. A. Teitell, and G. J. Schiller The Evolution of Antibodies into Versatile Tumor-Targeting Agents Clin. Cancer Res., January 1, 2005; 11(1): 129 - 138. [Abstract] [Full Text] [PDF]